The global market for Multiparametric In-vitro Cardiotoxicity Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Multiparametric In-vitro Cardiotoxicity Testing refers to a set of laboratory-based techniques and assays used to evaluate the potential toxic effects of drugs, chemicals, or other substances on the cardiovascular system. It involves the assessment of multiple parameters or endpoints to comprehensively evaluate the cardiac safety profile of a substance.

As the demands of drug development and chemical evaluation increase, the need for cardiotoxicity testing is also growing. Traditional animal testing methods have limitations such as high cost, long time, and ethical and moral issues, while Multiparametric in-vitro cardiotoxicity testing provides an alternative. By using cardiac cells, tissues or models, combined with multi-parameter measurements, it can more accurately evaluate the toxic effects of compounds on the heart, thereby improving the efficiency of drug safety assessment and chemical screening.

This report aims to provide a comprehensive presentation of the global market for Multiparametric In-vitro Cardiotoxicity Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiparametric In-vitro Cardiotoxicity Testing.

The Multiparametric In-vitro Cardiotoxicity Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiparametric In-vitro Cardiotoxicity Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Multiparametric In-vitro Cardiotoxicity Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Multiparametric In-vitro Cardiotoxicity Testing Market Report

Report Metric	Details
Report Name	Multiparametric In-vitro Cardiotoxicity Testing Market
Segment by Type	Calcium Transient Assay Cardiac Marker Detection Multi-ion Channel Assay Others
Segment by Application	Contract Research Organizations (CROs) Pharmaceutical and Biotech Companies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Hemogenix, Molecular Devices, Creative Bioarray, FUJIFILM Cellular Dynamics, Agilent Technologies, Merck KGaA, Axol Bioscience, Miltenyi Biotec, Evotec, Enzo Life Sciences, Stemina Biomarker Discovery, Eurofins Discovery
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiparametric In-vitro Cardiotoxicity Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

Ans: The main players in the Multiparametric In-vitro Cardiotoxicity Testing Market are Hemogenix, Molecular Devices, Creative Bioarray, FUJIFILM Cellular Dynamics, Agilent Technologies, Merck KGaA, Axol Bioscience, Miltenyi Biotec, Evotec, Enzo Life Sciences, Stemina Biomarker Discovery, Eurofins Discovery

What are the Application segmentation covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

Ans: The Applications covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report are Contract Research Organizations (CROs), Pharmaceutical and Biotech Companies, Others

What are the Type segmentation covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

Ans: The Types covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report are Calcium Transient Assay, Cardiac Marker Detection, Multi-ion Channel Assay, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Calcium Transient Assay

1.2.3 Cardiac Marker Detection

1.2.4 Multi-ion Channel Assay

1.2.5 Others

1.3 Market by Application

1.3.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Contract Research Organizations (CROs)

1.3.3 Pharmaceutical and Biotech Companies

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Perspective (2020-2031)

2.2 Global Multiparametric In-vitro Cardiotoxicity Testing Growth Trends by Region

2.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Region (2020-2025)

2.2.3 Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Region (2026-2031)

2.3 Multiparametric In-vitro Cardiotoxicity Testing Market Dynamics

2.3.1 Multiparametric In-vitro Cardiotoxicity Testing Industry Trends

2.3.2 Multiparametric In-vitro Cardiotoxicity Testing Market Drivers

2.3.3 Multiparametric In-vitro Cardiotoxicity Testing Market Challenges

2.3.4 Multiparametric In-vitro Cardiotoxicity Testing Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue

3.1.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue (2020-2025)

3.1.2 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Players (2020-2025)

3.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Multiparametric In-vitro Cardiotoxicity Testing Revenue

3.4 Global Multiparametric In-vitro Cardiotoxicity Testing Market Concentration Ratio

3.4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Multiparametric In-vitro Cardiotoxicity Testing Revenue in 2024

3.5 Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing Head office and Area Served

3.6 Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing, Product and Application

3.7 Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Type

4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Type (2020-2025)

4.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Type (2026-2031)

5 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Application

5.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic Market Size by Application (2020-2025)

5.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size (2020-2031)

6.2 North America Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025)

6.4 North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size (2020-2031)

7.2 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025)

7.4 Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size (2020-2031)

8.2 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2020-2025)

8.4 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size (2020-2031)

9.2 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025)

9.4 Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size (2020-2031)

10.2 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025)

10.4 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Hemogenix

11.1.1 Hemogenix Company Details

11.1.2 Hemogenix Business Overview

11.1.3 Hemogenix Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.1.4 Hemogenix Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.1.5 Hemogenix Recent Development

11.2 Molecular Devices

11.2.1 Molecular Devices Company Details

11.2.2 Molecular Devices Business Overview

11.2.3 Molecular Devices Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.2.4 Molecular Devices Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.2.5 Molecular Devices Recent Development

11.3 Creative Bioarray

11.3.1 Creative Bioarray Company Details

11.3.2 Creative Bioarray Business Overview

11.3.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.3.4 Creative Bioarray Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.3.5 Creative Bioarray Recent Development

11.4 FUJIFILM Cellular Dynamics

11.4.1 FUJIFILM Cellular Dynamics Company Details

11.4.2 FUJIFILM Cellular Dynamics Business Overview

11.4.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.4.4 FUJIFILM Cellular Dynamics Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.4.5 FUJIFILM Cellular Dynamics Recent Development

11.5 Agilent Technologies

11.5.1 Agilent Technologies Company Details

11.5.2 Agilent Technologies Business Overview

11.5.3 Agilent Technologies Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.5.4 Agilent Technologies Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.5.5 Agilent Technologies Recent Development

11.6 Merck KGaA

11.6.1 Merck KGaA Company Details

11.6.2 Merck KGaA Business Overview

11.6.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.6.4 Merck KGaA Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.6.5 Merck KGaA Recent Development

11.7 Axol Bioscience

11.7.1 Axol Bioscience Company Details

11.7.2 Axol Bioscience Business Overview

11.7.3 Axol Bioscience Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.7.4 Axol Bioscience Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.7.5 Axol Bioscience Recent Development

11.8 Miltenyi Biotec

11.8.1 Miltenyi Biotec Company Details

11.8.2 Miltenyi Biotec Business Overview

11.8.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.8.4 Miltenyi Biotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.8.5 Miltenyi Biotec Recent Development

11.9 Evotec

11.9.1 Evotec Company Details

11.9.2 Evotec Business Overview

11.9.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.9.4 Evotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.9.5 Evotec Recent Development

11.10 Enzo Life Sciences

11.10.1 Enzo Life Sciences Company Details

11.10.2 Enzo Life Sciences Business Overview

11.10.3 Enzo Life Sciences Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.10.4 Enzo Life Sciences Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.10.5 Enzo Life Sciences Recent Development

11.11 Stemina Biomarker Discovery

11.11.1 Stemina Biomarker Discovery Company Details

11.11.2 Stemina Biomarker Discovery Business Overview

11.11.3 Stemina Biomarker Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.11.4 Stemina Biomarker Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.11.5 Stemina Biomarker Discovery Recent Development

11.12 Eurofins Discovery

11.12.1 Eurofins Discovery Company Details

11.12.2 Eurofins Discovery Business Overview

11.12.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction

11.12.4 Eurofins Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

11.12.5 Eurofins Discovery Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Hemogenix

Creative Bioarray

Fujifilm Cellular Dynamics

Stemina Biomarker Discovery

List of Tables

Table 1. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Calcium Transient Assay

Table 3. Key Players of Cardiac Marker Detection

Table 4. Key Players of Multi-ion Channel Assay

Table 5. Key Players of Others

Table 6. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Region (2020-2025)

Table 10. Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Region (2026-2031)

Table 12. Multiparametric In-vitro Cardiotoxicity Testing Market Trends

Table 13. Multiparametric In-vitro Cardiotoxicity Testing Market Drivers

Table 14. Multiparametric In-vitro Cardiotoxicity Testing Market Challenges

Table 15. Multiparametric In-vitro Cardiotoxicity Testing Market Restraints

Table 16. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Players (2020-2025)

Table 18. Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiparametric In-vitro Cardiotoxicity Testing as of 2024)

Table 19. Ranking of Global Top Multiparametric In-vitro Cardiotoxicity Testing Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Multiparametric In-vitro Cardiotoxicity Testing Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing, Headquarters and Area Served

Table 22. Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing, Product and Application

Table 23. Global Key Players of Multiparametric In-vitro Cardiotoxicity Testing, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Type (2020-2025)

Table 27. Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Type (2026-2031)

Table 29. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Application (2020-2025)

Table 31. Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share by Application (2026-2031)

Table 33. North America Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size by Country (2026-2031) & (US$ Million)

Table 48. Hemogenix Company Details

Table 49. Hemogenix Business Overview

Table 50. Hemogenix Multiparametric In-vitro Cardiotoxicity Testing Product

Table 51. Hemogenix Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 52. Hemogenix Recent Development

Table 53. Molecular Devices Company Details

Table 54. Molecular Devices Business Overview

Table 55. Molecular Devices Multiparametric In-vitro Cardiotoxicity Testing Product

Table 56. Molecular Devices Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 57. Molecular Devices Recent Development

Table 58. Creative Bioarray Company Details

Table 59. Creative Bioarray Business Overview

Table 60. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Product

Table 61. Creative Bioarray Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 62. Creative Bioarray Recent Development

Table 63. FUJIFILM Cellular Dynamics Company Details

Table 64. FUJIFILM Cellular Dynamics Business Overview

Table 65. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Product

Table 66. FUJIFILM Cellular Dynamics Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 67. FUJIFILM Cellular Dynamics Recent Development

Table 68. Agilent Technologies Company Details

Table 69. Agilent Technologies Business Overview

Table 70. Agilent Technologies Multiparametric In-vitro Cardiotoxicity Testing Product

Table 71. Agilent Technologies Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 72. Agilent Technologies Recent Development

Table 73. Merck KGaA Company Details

Table 74. Merck KGaA Business Overview

Table 75. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Product

Table 76. Merck KGaA Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 77. Merck KGaA Recent Development

Table 78. Axol Bioscience Company Details

Table 79. Axol Bioscience Business Overview

Table 80. Axol Bioscience Multiparametric In-vitro Cardiotoxicity Testing Product

Table 81. Axol Bioscience Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 82. Axol Bioscience Recent Development

Table 83. Miltenyi Biotec Company Details

Table 84. Miltenyi Biotec Business Overview

Table 85. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Product

Table 86. Miltenyi Biotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 87. Miltenyi Biotec Recent Development

Table 88. Evotec Company Details

Table 89. Evotec Business Overview

Table 90. Evotec Multiparametric In-vitro Cardiotoxicity Testing Product

Table 91. Evotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 92. Evotec Recent Development

Table 93. Enzo Life Sciences Company Details

Table 94. Enzo Life Sciences Business Overview

Table 95. Enzo Life Sciences Multiparametric In-vitro Cardiotoxicity Testing Product

Table 96. Enzo Life Sciences Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 97. Enzo Life Sciences Recent Development

Table 98. Stemina Biomarker Discovery Company Details

Table 99. Stemina Biomarker Discovery Business Overview

Table 100. Stemina Biomarker Discovery Multiparametric In-vitro Cardiotoxicity Testing Product

Table 101. Stemina Biomarker Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 102. Stemina Biomarker Discovery Recent Development

Table 103. Eurofins Discovery Company Details

Table 104. Eurofins Discovery Business Overview

Table 105. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Product

Table 106. Eurofins Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025) & (US$ Million)

Table 107. Eurofins Discovery Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. Multiparametric In-vitro Cardiotoxicity Testing Picture

Figure 2. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Type: 2024 VS 2031

Figure 4. Calcium Transient Assay Features

Figure 5. Cardiac Marker Detection Features

Figure 6. Multi-ion Channel Assay Features

Figure 7. Others Features

Figure 8. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Application: 2024 VS 2031

Figure 10. Contract Research Organizations (CROs) Case Studies

Figure 11. Pharmaceutical and Biotech Companies Case Studies

Figure 12. Others Case Studies

Figure 13. Multiparametric In-vitro Cardiotoxicity Testing Report Years Considered

Figure 14. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Region: 2024 VS 2031

Figure 17. Global Multiparametric In-vitro Cardiotoxicity Testing Market Share by Players in 2024

Figure 18. Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiparametric In-vitro Cardiotoxicity Testing as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Multiparametric In-vitro Cardiotoxicity Testing Revenue in 2024

Figure 20. North America Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Multiparametric In-vitro Cardiotoxicity Testing Market Share by Country (2020-2031)

Figure 22. United States Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Share by Country (2020-2031)

Figure 26. Germany Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Share by Region (2020-2031)

Figure 34. China Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Multiparametric In-vitro Cardiotoxicity Testing Market Share by Country (2020-2031)

Figure 42. Mexico Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Market Share by Country (2020-2031)

Figure 46. Turkey Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Multiparametric In-vitro Cardiotoxicity Testing Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Hemogenix Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 50. Molecular Devices Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 51. Creative Bioarray Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 52. FUJIFILM Cellular Dynamics Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 53. Agilent Technologies Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 54. Merck KGaA Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 55. Axol Bioscience Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 56. Miltenyi Biotec Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 57. Evotec Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 58. Enzo Life Sciences Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 59. Stemina Biomarker Discovery Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 60. Eurofins Discovery Revenue Growth Rate in Multiparametric In-vitro Cardiotoxicity Testing Business (2020-2025)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-19E17259

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Rehabilitation Evaluation Equipment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-39U17029

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Modular Healthcare Buildings Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-24Y16719

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Digital Telepathology Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0S20450

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Multiparametric In-vitro Cardiotoxicity Testing Market Research Report 2025

Published Date: April 2025

Report Code: QYRE-Auto-11N13498

Global Multiparametric In-vitro Cardiotoxicity Testing Market Research Report 2025

FEATURED COMPANIES

Multiparametric In-vitro Cardiotoxicity Testing Market

Scope of Multiparametric In-vitro Cardiotoxicity Testing Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

What are the Application segmentation covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

What are the Type segmentation covered in the Multiparametric In-vitro Cardiotoxicity Testing Market report?

FEATURED COMPANIES

RELATED REPORTS